Congress Eyes State-Driven Drug Rescheduling for Cannabis, Psychedelics
New federal legislation would empower states to petition for drug reclassification, potentially accelerating cannabis reform through state-level advocacy.
A new congressional bill proposes a fundamental shift in federal drug policy by allowing states to petition for the reclassification of controlled substances, including cannabis and psychedelics. The legislation would create a formal mechanism for state governments to challenge federal scheduling decisions, potentially accelerating reform efforts that have stalled at the federal level.
The proposal represents a significant departure from current drug policy framework, where the Drug Enforcement Administration maintains exclusive authority over controlled substance classifications. Under the new system, states could build coalitions to challenge federal scheduling through documented evidence of medical benefits, safety profiles, and economic impact data. This bottom-up approach mirrors successful state-level cannabis legalization campaigns that ultimately pressured federal agencies to reconsider enforcement priorities.
For cannabis operators, the legislation offers a potential pathway around the current rescheduling bottleneck that has left the industry in regulatory limbo. Major multi-state operators like Curaleaf (OTCQX: CURLF) and Green Thumb Industries (OTCQX: GTBIF) continue trading on over-the-counter markets due to federal prohibition, limiting institutional investment and access to traditional banking services. State-driven rescheduling could expedite the timeline for federal reform that would unlock these operational barriers.
The bill's introduction comes as cannabis companies face mounting pressure from high tax burdens under Section 280E and limited access to capital markets. Cannabis stocks have underperformed broader markets throughout 2024, with the AdvisorShares Pure US Cannabis ETF (MSOS) down approximately 15% year-to-date. Industry executives have repeatedly cited federal scheduling as the primary obstacle to profitability and growth.
While the legislation faces uncertain prospects in a divided Congress, it signals growing bipartisan recognition that current federal drug policy lags behind state-level reforms. Twenty-four states have legalized adult-use cannabis, creating a patchwork of conflicting federal and state laws that complicates business operations and regulatory compliance. The proposed state petition process could provide a more pragmatic approach to drug policy reform that reflects evolving public opinion and scientific evidence.